Cipla to distribute Roches anti-body cocktail, a Covid-19 treatment drug in India

Cipla Limited, a leading pharmaceutical company announced today that it is going to distribute an anti-body of Casirivimab and Imdevimab drugs across India.  This anti-body cocktail is a product of Roche Pharma India. 

The anti-body cocktail is to be used in the treatment of patients with mild to moderate Covid-19 disease. 

The pre-requisites for patients who can receive this treatment are- they should be 12 years and above, weigh at least 40 kilograms, stand at a risk of developing severe COVID-19 disease and do not require oxygen.   

The company announced that the first batch of the anti-body cocktail is now available in the country whereas the second batch, which is under production, will be available by mid-June. The total number of packs that will be produced in these two batches stand at 1 lakh and are expected to benefit 2 lakh patients as each pack offers treatment for two patients.       

The cocktail has an emergency use authorization which is provided by the Central Drugs Standards Control Organisation (CDSCO). By leveraging its strong distribution foothold across the country, Cipla will make the anti-body cocktail available through leading hospitals and COVID treatment centers. 

At 2.09 pm, the share price of Cipla Limited was trading at Rs 932.25 on BSE, an increase of 0.58 per cent over the previous closing price of Rs 926.85 on Friday.